Page last updated: 2024-11-03

propranolol and Allodynia

propranolol has been researched along with Allodynia in 16 studies

Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.

Research Excerpts

ExcerptRelevanceReference
"Resveratrol significantly decreased thermal allodynia (and not anxiety) in all experimental days."4.02Intracerebroventricular injection of propranolol blocked analgesic and neuroprotective effects of resveratrol following L ( Bahari, Z; Bahrami, F; Ghasemi, M; Hosseini, M; Iman, M; Mohammadi, MT; Zabihian, MA, 2021)
" Results VL-102-evoked acute and chronic mechanical cephalic and hind-paw allodynia in a dose-dependent manner, which was blocked by the migraine medications sumatriptan, propranolol, and topiramate."3.88Soluble guanylyl cyclase is a critical regulator of migraine-associated pain. ( Ben Aissa, M; Bennett, BM; Bertels, Z; Gaisina, IN; Gandhi, R; Lee, SH; Litosh, V; Moye, LS; Novack, M; Pradhan, AA; Thatcher, GR; Tipton, AF; Wang, Y, 2018)
"A genetic analysis of opioid-induced hyperalgesia in mice linked the β(2)-adrenergic receptor to mechanical sensitization after opioid exposure."2.77Modulation of remifentanil-induced postinfusion hyperalgesia by the β-blocker propranolol in humans. ( Angst, MS; Chu, LF; Clark, DJ; Cun, T; Kim, JE; Ngai, LK; Young, CA; Zamora, AK, 2012)
"Pretreatment with propranolol or nor-BNI prior to restraint stress prevented both transient cutaneous allodynia and priming, demonstrated by a lack of umbellulone-induced cutaneous allodynia."1.62A novel, injury-free rodent model of vulnerability for assessment of acute and preventive therapies reveals temporal contributions of CGRP-receptor activation in migraine-like pain. ( Chessell, IP; Dodick, DW; Kopruszinski, CM; Navratilova, E; Porreca, F; Swiokla, J, 2021)
"Therapeutic potential of agomelatine on neuropathic pain was suppressed with α-methyl-para-tyrosine methyl ester (an inhibitor of catecholamine synthesis), phentolamine (a nonselective α-adrenoceptor antagonist), and propranolol (a nonselective β-adrenoceptor antagonist) administrations."1.43Effect of subacute agomelatine treatment on painful diabetic neuropathy: involvement of catecholaminergic mechanisms. ( Aydın, TH; Can, ÖD; Demir Özkay, Ü; Turan, N, 2016)
"injection abolished carrageenan-evoked hyperalgesia at the doses, at which the drugs failed to alter the hypersensitivity when they were given alone."1.39Effects of a combination of ketanserin and propranolol on inflammatory hyperalgesia in rats. ( Hong, Y; Wang, D; Zhou, X, 2013)
" In vagotomized rats, chronic administration of ICI 118,551 markedly attenuated vagotomy-induced enhancement of bradykinin hyperalgesia but had no effect on nociceptive threshold."1.32Vagal modulation of nociception is mediated by adrenomedullary epinephrine in the rat. ( Green, PG; Khasar, SG; Levine, JD; Miao, FJ, 2003)
"Mechanical hyperalgesia, however, was less sensitive to inhibition by propranolol and guanethedine but significantly inhibited by phentolamine."1.31The role of the sympathetic efferents in endotoxin-induced localized inflammatory hyperalgesia and cytokine upregulation. ( Haddad, JJ; Jabbur, SJ; Massaad, CA; Poole, S; Saadé, NE; Safieh-Garabedian, B, 2002)
"Bradykinin-induced hyperalgesia was abolished by HOE 140 and by treatment of the paws with anti-TNF-alpha antisera."1.29Bradykinin release of TNF-alpha plays a key role in the development of inflammatory hyperalgesia. ( Cunha, FQ; Ferreira, SH; Lorenzetti, BB; Poole, S, 1993)

Research

Studies (16)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (6.25)18.2507
2000's3 (18.75)29.6817
2010's10 (62.50)24.3611
2020's2 (12.50)2.80

Authors

AuthorsStudies
Kopruszinski, CM1
Navratilova, E1
Swiokla, J1
Dodick, DW1
Chessell, IP1
Porreca, F1
Zabihian, MA1
Hosseini, M1
Bahrami, F1
Iman, M1
Ghasemi, M1
Mohammadi, MT1
Bahari, Z1
Boyer, N1
Signoret-Genest, J1
Artola, A1
Dallel, R1
Monconduit, L1
Ben Aissa, M1
Tipton, AF1
Bertels, Z1
Gandhi, R1
Moye, LS1
Novack, M1
Bennett, BM1
Wang, Y1
Litosh, V1
Lee, SH1
Gaisina, IN1
Thatcher, GR1
Pradhan, AA1
Romero, TRL1
Soares Santos, RR1
Castor, MGME1
Petrocchi, JA1
Guzzo, LS1
Klein, A1
Duarte, IDG1
Wang, D1
Zhou, X1
Hong, Y1
Park, PE1
Schlosburg, JE1
Vendruscolo, LF1
Schulteis, G1
Edwards, S1
Koob, GF1
Aydın, TH1
Can, ÖD1
Demir Özkay, Ü1
Turan, N1
Long, Q1
Liu, X1
Qi, Q1
Guo, SW1
Chu, LF1
Cun, T1
Ngai, LK1
Kim, JE1
Zamora, AK1
Young, CA1
Angst, MS1
Clark, DJ1
Werner, MU1
Barchini, J1
Tchachaghian, S1
Shamaa, F1
Jabbur, SJ2
Meyerson, BA1
Song, Z1
Linderoth, B1
Saadé, NE2
Khasar, SG1
Green, PG1
Miao, FJ1
Levine, JD1
Ferreira, SH1
Lorenzetti, BB1
Cunha, FQ1
Poole, S2
Ernberg, M1
Lundeberg, T1
Kopp, S1
Safieh-Garabedian, B1
Haddad, JJ1
Massaad, CA1

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Effect of Beta Blockade on Opioid-Induced Hyperalgesia in Humans[NCT01222091]Phase 210 participants (Actual)Interventional2009-02-28Completed
The Serotonin Receptor Type 3 Antagonist Granisetron as a New Treatment Approach for Patients With Chronic Myofascial Pain in the Orofacial Muscles[NCT02230371]Phase 440 participants (Actual)Interventional2007-03-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Objective Opioid Withdrawal Scale (OOWS)

OOWS: Is a 13-item instrument of documenting physically observable signs of withdrawal, which are rated as present (1) or absent (0) during the observation period. Maximum score = 13, minimum score = 0. Lower scores correspond to fewer symptoms. (NCT01222091)
Timeframe: Pretreatment [90 min prior to 60-min REM infusion]; 30 min prior to 60-min REM infusion; 15 and 40 min after start of 60-min REM infusion; 5, 15, and 75 minutes after finish of 60-min REM infusion)

,
Interventionunits on a scale (Mean)
Pretreatment30 min prior to REM infusion15 min after start of REM infusion40 min after start of REM infusion5 minutes after finish of REM infusion15 minutes after finish of REM infusion75 minutes after finish of REM infusion
Placebo1.11.10.80.51.82.11.6
Propranolol1.21.10.10.832.81.7

Percent Change From Baseline in Size (Area) of Secondary Hyperalgesia After Cessation of Remifentanil Infusion, a Measure of Opioid-induced Hyperalgesia (OIH).

A slightly modified version of a previously described model of secondary hyperalgesia was used. Two copper wires contained in a microdialysis catheter were inserted in parallel over a length of 5 mm into the dermis of the right volar forearm. The wires were connected to a constant current stimulator controlled by a pulse generator to deliver rectangular and monophasic pulses with a duration of 0.5 mg at 2 Hz. Over a period of 15 min, the current was increased by targeting a pain rating of 5 on an 11-point numeric rating scale (0 = no pain and 10 = maximum tolerable pain) until the hyperalgesic area surrounding the stimulation site was fully established. Once the area was established, the current was held constant. Percent change from baseline in size (area) of secondary hyperalgesia after cessation of remifentanil infusion was calculated per group. (NCT01222091)
Timeframe: Baseline; 15 min post remifentanil (REM) infusion; 60 min post REM infusion

,
Interventionpercentage of change (Number)
15 min post remifentanil infusion60 min post remifentanil infusion
Placebo-34141.5
Propranolol-28-19

Trials

2 trials available for propranolol and Allodynia

ArticleYear
Modulation of remifentanil-induced postinfusion hyperalgesia by the β-blocker propranolol in humans.
    Pain, 2012, Volume: 153, Issue:5

    Topics: Adolescent; Adult; Analgesics; Cross-Over Studies; Double-Blind Method; Humans; Hyperalgesia; Male;

2012
Effect of propranolol and granisetron on experimentally induced pain and allodynia/hyperalgesia by intramuscular injection of serotonin into the human masseter muscle.
    Pain, 2000, Volume: 84, Issue:2-3

    Topics: Adult; Double-Blind Method; Drug Combinations; Female; Granisetron; Humans; Hyperalgesia; Injections

2000

Other Studies

14 other studies available for propranolol and Allodynia

ArticleYear
A novel, injury-free rodent model of vulnerability for assessment of acute and preventive therapies reveals temporal contributions of CGRP-receptor activation in migraine-like pain.
    Cephalalgia : an international journal of headache, 2021, Volume: 41, Issue:3

    Topics: Animals; Calcitonin Gene-Related Peptide; Disease Models, Animal; Female; Hyperalgesia; Male; Mice;

2021
Intracerebroventricular injection of propranolol blocked analgesic and neuroprotective effects of resveratrol following L
    Journal of complementary & integrative medicine, 2021, May-10, Volume: 18, Issue:4

    Topics: Analgesics; Animals; Disease Models, Animal; Hyperalgesia; Ligation; Male; Neuroprotective Agents; P

2021
Propranolol treatment prevents chronic central sensitization induced by repeated dural stimulation.
    Pain, 2017, Volume: 158, Issue:10

    Topics: Adrenergic beta-Antagonists; Afferent Pathways; Animals; Central Nervous System Sensitization; Chlor

2017
Soluble guanylyl cyclase is a critical regulator of migraine-associated pain.
    Cephalalgia : an international journal of headache, 2018, Volume: 38, Issue:8

    Topics: Adrenergic beta-Antagonists; Allosteric Regulation; Animals; Anticonvulsants; Calcitonin Gene-Relate

2018
Noradrenaline induces peripheral antinociception by endogenous opioid release.
    Pharmacological reports : PR, 2018, Volume: 70, Issue:4

    Topics: Analgesics; Animals; Cinnamates; Dinoprostone; Dose-Response Relationship, Drug; Hyperalgesia; Leuci

2018
Effects of a combination of ketanserin and propranolol on inflammatory hyperalgesia in rats.
    European journal of pharmacology, 2013, Dec-05, Volume: 721, Issue:1-3

    Topics: Analgesics; Animals; Arthritis; Carrageenan; Dose-Response Relationship, Drug; Drug Interactions; Hy

2013
Chronic CRF1 receptor blockade reduces heroin intake escalation and dependence-induced hyperalgesia.
    Addiction biology, 2015, Volume: 20, Issue:2

    Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-2 Receptor Agonists; Adrenergic beta-Antag

2015
Effect of subacute agomelatine treatment on painful diabetic neuropathy: involvement of catecholaminergic mechanisms.
    Fundamental & clinical pharmacology, 2016, Volume: 30, Issue:6

    Topics: Acetamides; Animals; Blood Glucose; Catecholamines; Diabetes Mellitus, Experimental; Diabetic Neurop

2016
Chronic stress accelerates the development of endometriosis in mouse through adrenergic receptor β2.
    Human reproduction (Oxford, England), 2016, Volume: 31, Issue:11

    Topics: Adrenergic alpha-1 Receptor Agonists; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals

2016
Vanguard research in opioid-induced hyperalgesia - but guard the basics.
    Pain, 2012, Volume: 153, Issue:5

    Topics: Analgesics; Humans; Hyperalgesia; Male; Piperidines; Propranolol; Remifentanil

2012
Spinal segmental and supraspinal mechanisms underlying the pain-relieving effects of spinal cord stimulation: an experimental study in a rat model of neuropathy.
    Neuroscience, 2012, Jul-26, Volume: 215

    Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Analysis of Variance; Animals; Baclofen;

2012
Vagal modulation of nociception is mediated by adrenomedullary epinephrine in the rat.
    The European journal of neuroscience, 2003, Volume: 17, Issue:4

    Topics: Adrenal Medulla; Adrenergic beta-Antagonists; Animals; Behavior, Animal; Bradykinin; Dose-Response R

2003
Bradykinin release of TNF-alpha plays a key role in the development of inflammatory hyperalgesia.
    Agents and actions, 1993, Volume: 38 Spec No

    Topics: Animals; Bradykinin; Dose-Response Relationship, Drug; Hindlimb; Hyperalgesia; Indomethacin; Inflamm

1993
The role of the sympathetic efferents in endotoxin-induced localized inflammatory hyperalgesia and cytokine upregulation.
    Neuropharmacology, 2002, Volume: 42, Issue:6

    Topics: Adrenergic alpha-Antagonists; Adrenergic Antagonists; Adrenergic Fibers; Animals; Cytokines; Dose-Re

2002